2009-2013年国内药物经济学评价类文献之质量分析

发布时间：2018-10-22 20:35

【摘要】：目的:了解近几年国内药物经济学评价的研究水平,为其提高提供参考。方法:采用一个包含5项一级指标、24项二级指标的评价框架对2009-2013年国内专业学术期刊上发表的1 127篇药物经济学评价文献进行质量分析,分析内容包括所有文献的总体质量以及根据研究者类型、是否表明获得资助以及评价方法类型进行的亚组分析。结果:国内药物经济学评价文献质量整体偏低,仅为0.347分(SD=0.476);明确表明经费来源(P=0.006)、采用成本-效用分析(P=0.003)及多种分析方法(P=0.061)的文献质量显著高于总体文献。结论:我国的药物经济学研究需要进一步规范和完善,以获得可靠的评价结果并用于指导实践。
[Abstract]:Objective: to understand the research level of pharmacoeconomics evaluation in China in recent years and to provide reference for its improvement. Methods: 1 127 pharmacoeconomic evaluation papers published in professional academic journals in China from 2009 to 2013 were analyzed by an evaluation framework consisting of 5 first-degree indicators and 24 second-level indicators. The analysis included the overall quality of all literature and subgroup analysis based on the type of researcher, whether funding was received and the type of evaluation method. Results: the literature quality of pharmacoeconomics evaluation in China was on the low side, only 0.347 points (SD=0.476), which clearly indicated that the funding sources (P0. 006), cost-utility analysis (P0. 003) and various analytical methods (P0. 061) were significantly higher than the overall literature. Conclusion: the pharmacoeconomics research in China needs to be further standardized and improved in order to obtain reliable evaluation results and guide practice.
【作者单位】：贵阳医学院医药卫生管理学院;
【基金】：国家自然科学基金资助项目(No.71463007) 贵州省科技厅计划课题(No.黔科合SY字[2013]3068号) 贵州省教育厅高校人文社会科学研究项目(No.黔教社发[2013]419号) 贵阳医学院基金项目(No.院基金合同字第[2013]05号)
【分类号】：R95;G353.1

【参考文献】